Investigate the heterogeneity of colorectal cancer patients at the single-cell level prior to and subsequent to immunotherapy - Top-Institutions - MDSpire

Investigate the heterogeneity of colorectal cancer patients at the single-cell level prior to and subsequent to immunotherapy

  • By

  • Heng Zhao

  • Gao Wu

  • Junhong Zhao

  • Qianwen Wang

  • Wenkang Cheng

  • Jie Li

  • Jin Yang

  • May 4, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Immunotherapy

  • #2

    Kimmel Cancer Center at Johns Hopkins University
    Kimmel Cancer Center at Johns Hopkins University

    Baltimore, Maryland

    Key Differentiators

    • Oncology
    • Immunotherapy

  • #3

    The University of Hong Kong
    The University of Hong Kong

    Hong Kong, N/A

    Key Differentiators

    • Oncology

  • #4

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Immunotherapy

  • #5

    First Affiliated Hospital of Zhengzhou University
    First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan

    Key Differentiators

    • Oncology

Original Source(s)

Investigate the heterogeneity of colorectal cancer patients at the single-cell level prior to and subsequent to immunotherapy

  • by Heng Zhao, Gao Wu, Junhong Zhao, Qianwen Wang, Wenkang Cheng, Jie Li, Jin Yang

  • May 4, 2026

Related Content

CD38+ NK cells: novel players in immunoregulation

Baicalin suppresses colorectal cancer proliferation and induces M1 polarization of tumor-associated macrophages by promoting proteasomal degradation of HK2

A Meta-Analysis on the Effectiveness and Safety of FOLFOX Plus Bevacizumab for Colorectal Cancer Treatment